A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
Authors:
- 1 June 2014
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14 (3) , 223-230
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary MyelofibrosisPLOS ONE, 2013
- Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic targetLeukemia, 2012
- Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemiaBlood, 2011
- The potential role of Aurora kinase inhibitors in haematological malignanciesBritish Journal of Haematology, 2011
- Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemiasLeukemia, 2010
- Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProceedings of the National Academy of Sciences, 2005
- Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis.Oncology Reports, 2004
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Mitotic Kinase Expression and Colorectal Cancer ProgressionJNCI: Journal of the National Cancer Institute, 1999
- A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell linesOncogene, 1997